Science 37® and CMIC Announce Partnership to Advance Decentralized Clinical Trials in Japan/APAC and Speed Drug Development
LOS ANGELES and TOKYO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Science 37, the Operating System for todays more agile clinical trials, and CMIC HOLDINGS Co., Ltd. (CMIC), the largest CRO in Japan today announced a partnership to further decentralized clinical trials and to help speed the development of treatments.
- LOS ANGELES and TOKYO, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Science 37, the Operating System for todays more agile clinical trials, and CMIC HOLDINGS Co., Ltd. (CMIC), the largest CRO in Japan today announced a partnership to further decentralized clinical trials and to help speed the development of treatments.
- In this collaboration, CMIC will use Science 37s clinical trial Operating System and its end-to-end technology platform to help orchestrate workflows, generate evidence and harmonize data for global decentralized studieshelping speed study timelines.
- Decentralized trials, enabled by technology, can alleviate these burdenshelping to drive efficiency, reduce costs and enabling more patients to participate.
- Through this partnership, CMIC becomes part of the Science 37 CRO Certified network, designed to empower CROs with access, training, and commercial support to successfully deliver decentralized clinical studies at scale.